免费注册

IGF及其受体家族——蓄势待发的靶向通路

胰岛素样生长因子（Insulin like growth factor，IGF）是一组具有促生长作用的多肽类物质，以自分泌、旁分泌和内分泌的形式在促进细胞增殖、分化和存活方面发挥着关键的作用。IGF轴有I型IGF（IGF-I）和II型IGF（IGF-II）两种，它们通过结合特定的糖蛋白膜受体IGF-IR和IGF-IIR发挥作用。
IGF-IR 是IGF家族中的一个关键成员，具有四聚体结构，由二硫键连接的两个α亚基和两个跨膜β亚基组成。IGF-IR通路的激活对癌症的起始和生长至关重要，许多类型的肿瘤细胞会过表达IGF-IR，从而导致多种癌症对放疗、化疗和靶向治疗产生耐药，因此通过靶向IGF/IGF-IR抑制IGF-IR信号来消除癌细胞成为一种癌症治疗策略。靶向IGF-IR的代表性药物Teprotumumab于2020年被美国食品和药物管理局（FDA）批准用于治疗甲状腺相关性眼病（TAO）。前瞻性研究表明，联合靶向IGF-IR和STAT3可能抑制肿瘤转移，并克服STAT3介导的抗IGF-IR治疗的耐药性，最大限度地提高癌症治疗的疗效。
抑制IGF-IR信号传导的治疗策略

抑制IGF-IR信号传导的治疗策略

https://doi.org/10.1016/j.gendis.2022.03.002
IGF靶向药物示意图

IGF靶向药物示意图

https://doi.org/10.3390/ijms231911781
ACROBiosystems百普赛斯开发了HEK293表达的IGF及其受体家族系列蛋白，包括IGF-IR四聚体蛋白、IGF-I、IGF-II、IGFBP-3、IGFBP-4、IGFBP-7，产品齐全，有多种属、多标签、生物素标记的产品可供选择，高纯度和高结构均一性经SDS-PAGE/SEC-MALS验证，高生物活性经ELISA/SPR验证，严格的质控体系保证性能稳定，适用于免疫、抗体药物筛选与表征，为靶向IGF的药物研发助力。

产品列表

验证数据

高纯度及高结构均一性经SDS-PAGE及SEC-MALS验证
IGR-H5229

The purity of Human IGF-I R, His Tag (Cat. No. IGR-H5229) is more than 90% and the molecular weight of this protein is around 252-308 kDa verified by SEC-MALS.

高生物活性经ELISA验证
IGR-H5229

Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I Protein, Fc Tag (Cat. No. IG1-H5263) with a linear range of 0.01-0.156 μg/mL (Routinely tested).


Protocol

IGR-H5229

Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGF-I, Avitag,Fc Tag (Cat. No. IG1-H82F7) with a linear range of 0.02-0.625 μg/mL (QC tested).

Protocol

高生物活性经SPR验证
IG7-H5240

Human IGFBP-7, His Tag (Cat. No.IG7-H5240) immobilized on CM5 Chip can bind Human C1q R1, His Tag (Cat. No. C11-H5228) with an affinity constant of 16.7 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

IGR-H5229

Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No. IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) .

Protocol

相关阅读

> 【靶点新势力】IGF-IR靶向眼疾治疗国内“首破冰”

参考文献

  • [1] Wang P, Mak V C Y, Cheung L W T. Drugging IGF-1R in cancer: new insights and emerging opportunities[J]. Genes & Diseases, 2022.https://doi.org/10.1016/j.gendis.2022.03.002.
  • [2] Lin S L, Lin C Y, Lee W, et al. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine[J]. International Journal of Molecular Sciences, 2022, 23(19): 11781.https://doi.org/10.3390/ijms231911781.
  • [3] Morrione A, Belfiore A. Obesity, Diabetes, and Cancer: The Role of the Insulin/IGF Axis; Mechanisms and Clinical Implications[J]. Biomolecules, 2022, 12(5): 612.https://doi.org/10.3390/biom12050612.
  • 背景介绍
  • 产品列表
  • 验证数据
  • 参考文献